The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

For Immediate Release

Chicago, IL – September 11, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Goldman Sachs Group, Inc. GS, RTX Corp. RTX, Abbott Laboratories ABT, NLI Holdings, Inc. NL and Precipio, Inc. PRPO.

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for Goldman Sachs, RTX and Abbott

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc., RTX Corp. and Abbott Laboratories, as well as two micro-cap stocks NLI Holdings, Inc. and Precipio, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Today's Featured Research Reports

Goldman Sachs’ shares have outperformed the Zacks Financial - Investment Bank industry over the past year (+33.7% vs. +22.5%). The company’s earnings surpassed estimates in each of the trailing four quarters. Goldman Sachs is prioritizing durable revenue streams, with improving deal activity and a strong investment banking backlog supporting fee-income growth. The recent IG Wealth Management collaboration, along with the planned LCN and NEOS acquisitions, is likely to further strengthen Asset & Wealth Management.

However, the rising expense base might hamper its near-term profitability. Elevated provisions amid a volatile macro backdrop remain a key concern. Its high dependence on overseas revenues is worrisome.

Nevertheless, the company’s private credit expansion is expected to diversify revenues and drive long-term growth. Its strong capital and liquidity position will continue to support shareholder returns.

(You can read the full research report on Goldman Sachs here >>>)

Shares of RTX have outperformed the Zacks Aerospace - Defense industry over the past year (+27.2% vs. -9.5%). The company is supported by a steady recovery in commercial aerospace, strong defense orders and robust backlog. Rising global air traffic, higher commercial OEM and aftermarket sales and strong demand for large commercial engines should aid growth.

RTX's defense business remains well-positioned, backed by strong bookings from the Pentagon and foreign allies. The company ended the second quarter of 2026 with a backlog of $289 billion. Its cash generation funds expansion, innovation and debt reduction.

However, persistent supply-chain disruptions remain a concern. Aircraft engine availability issues may affect production and deliveries. Tariff-related uncertainty and expanded Russia-linked sanctions also pose risks to RTX’s operations. The Zacks analyst have a Neutral rating on RTX shares.

(You can read the full research report on RTX here >>>)

Abbott’s shares have declined -18.9% over the past year against the Zacks Medical - Products industry’s decline of -28.9%. The company’s Rapid and Molecular Diagnostics remain exposed to respiratory testing volatility, China pricing policies still constrain Core Laboratory growth, and Exact Sciences adds integration, financing and dilution risks. With full-year sales guidance maintained and EPS guidance raised, the risk-reward profile is balanced for a Neutral view.

Nevertheless, Abbott’s diversified portfolio supports steady underlying growth, led by Medical Devices, FreeStyle Libre and Established Pharmaceuticals. Core Laboratory demand remains resilient, while Cancer Diagnostics adds an oncology platform and a faster-growing screening franchise.

Nutrition is showing sequential improvement as pricing actions, WIC wins and new products support volume recovery. A steady pipeline across electrophysiology, structural heart and diabetes should sustain product-led growth.

(You can read the full research report on Abbott here >>>)

Shares of NLI have outperformed the Zacks Electronics - Miscellaneous Components industry over the past year (+15.6% vs. -11.7%). This microcap company with a market capitalization of $330.07 million benefits from a diversified earnings base, established competitive positions and improving operating efficiency across CompX and Kronos.

Broad-based demand in Security Products, industrial growth in Marine Components and Kronos’ lower cost structure support earnings resilience and the operating outlook. Strong liquidity also provides flexibility for investment, dividends and legacy obligations.

However, NL remains materially exposed to Kronos and the cyclical TiO2 market, where pricing recovery is incomplete, and low-cost global supply could constrain sustained margin expansion. Environmental and litigation obligations remain difficult to predict, while currency volatility can offset operating improvements at Kronos and reduce the visibility of NL’s earnings recovery.

(You can read the full research report on NLI here >>>)

Precipio’s shares have outperformed the Zacks Medical Info Systems industry over the past year (+26.5% vs. -16%). This microcap company with a market capitalization of $45.83 million has an investment case which rests on rising pathology volumes, improving margins and a developing products business. Pathology growth is supporting service revenues, while the Products division is benefiting from distributor expansion, a growing pipeline and commercialization of the rapid AML assay.

The integrated pathology-product model may provide operating leverage as internally validated diagnostics are scaled externally. Liquidity and operating cash flow improved, although profitability remains uneven.

However, key risks include slower pipeline conversion, shipment timing, customer concentration, reimbursement and pricing-mix pressure, supplier obligations, cybersecurity litigation and funding sensitivity. The valuation points to restrained investor expectations, creating upside potential if revenue growth, margin improvement and operating consistency strengthen.

(You can read the full research report on Precipio here >>>)

Free: Instant Access to Zacks' Market-Crushing Strategies

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.

Get all the details here >>

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

NLI Holdings, Inc. (NL): Free Stock Analysis Report

Precipio, Inc. (PRPO): Free Stock Analysis Report

RTX Corporation (RTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research